Author

Richard S Strauss 1

1 Janssen R&D, LLC.

EARLY AND SUSTAINED REMISSION AFTER TREATMENT WITH SC ADMINISTERED GOLIMUMAB IS ASSOCIATED WITH NORMALIZED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: POSTHOC-ANALYSIS FROM PURSUIT INDUCTION AND MAIN

Walter Reinisch, Brian G. Feagan, Colleen W. Marano, Richard S Strauss, C. Han, T Gathany, Jewel Johanns, Hongjie Zhang, Peter R. Gibson, John Collins, Paul Rutgeerts, Jean-Frederic Colombel, Brian G. Feagan, Gunnar Jarnerot, William Sandborn

EARLY RESPONSES IN PATIENT-REPORTED OUTCOMES ARE PREDICTORS FOR MUCOSAL HEALING IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH GOLIMUMAB- RESULTS FROM PURSUIT SC INDUCTION

Walter Reinisch, Brian G. Feagan, Colleen W. Marano, Richard S Strauss, C. Han, Jewel Johanns, Hongjie Zhang, Peter R. Gibson, John Collins, Paul Rutgeerts, William Sandborn, Jean-Frederic Colombel, Brian G. Feagan, Gunnar Jarnerot

EFFECTS OF IMMUNOMODULATORS ON THE PHARMACOKINETICS AND EFFICACY OF GOLIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM PHASE 2/3 PURSUIT –SC INDUCTION AND MAINTENANCE STUDIES

Zhi-jie Xu, Colleen W. Marano, Richard S Strauss, Hongjie Zhang, H M Davis, Walter Reinisch, Brian G. Feagan, Paul Rutgeerts, Omoniyi J. Adedokun, Jean-Frederic Colombel, William Sandborn

FECAL LACTOFERRIN AND CALPROTECTIN AS SURROGATE MARKERS OF MUCOSAL HEALING: POST-HOC ANALYSIS FROM THE PURSUIT SC INDUCTION STUDY

Walter Reinisch, William Sandborn, Brian G. Feagan, Paul Rutgeerts, Peter R. Gibson, Judy Collins, Dino Tarabar, Zbigniew Hebzda, Jean-Frederic Colombel, Colleen W. Marano, Richard S Strauss, Jewel Johanns, Hongyan Zhang

HOW LONG SHOULD GOLIMUMAB TREATMENT BE CONTINUED IN PATIENTS WITH ULCERATIVE COLITIS WHO DO NOT RESPOND TO INITIAL INDUCTION THERAPY?

Paul Rutgeerts, Walter Reinisch, Brian G. Feagan, William Sandborn, Dino Tarabar, Zbigniew Hebzda, Ruji Yao, Colleen W. Marano, Richard S Strauss

PATIENT-REPORTED OUTCOMES CAN BE USED TO MONITOR CONTINUOUS CLINICAL RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH GOLIMUMAB: RESULTS FROM THE PURSUIT MAINTENANCE STUDY

Walter Reinisch, Jean-Frederic Colombel, Brian G. Feagan, Chenglong Han, Colleen W. Marano, Richard S Strauss, Peter R. Gibson, William Sandborn, Susan Huyck, Freddy Cornillie, Paul Rutgeerts

RELATIONSHIP BETWEEN CLINICAL OUTCOMES AND DISEASE DURATION, EXTENT, AND SEVERITY IN PATIENTS WITH ULCERATIVE COLITIS WHO RECEIVED 6 WEEKS OF TREATMENT WITH GOLIMUMAB

William Sandborn, Brian G. Feagan, Jean-Frederic Colombel, Walter Reinisch, Peter R. Gibson, Paul Rutgeerts, Ruji Yao, Colleen W. Marano, Richard S Strauss

WEIGHT-BASED MAINTENANCE DOSING OF GOLIMUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

Paul Rutgeerts, Walter Reinisch, Brian G. Feagan, William Sandborn, Dino Tarabar, Zbigniew Habzda, Ruji Yao, Colleen W. Marano, Richard S Strauss

Item 1 - 8 / 11
1
2